Page 20 - Flipbook
P. 20
Maintenance avelumab improves OS and PFS
38- months median follow-up data shows median OS of 23.8 months with Avelumab + BSC vs 15 months with BSC alone
(Powles et al. ASCO GU 2022)
Thomas Powles et al. NEJM 2020
